Upadacitinib Clears Atopic Dermatitis Faster Than Dupilumab | 合法藥品大搜索

2021年4月23日—UpadacitinibClearsAtopicDermatitisFasterThanDupilumab...AnoralJanuskinase1(JAK1)inhibitor,upadacitinib(Rinvoq),relievesthe ...

An oral Janus kinase 1 (JAK1) inhibitor, upadacitinib (Rinvoq), relieves the symptoms of atopic dermatitis (AD) better than dupilumab (Dupixent), researchers say.

"The differences between the two drugs were more pronounced when we looked at higher levels of improvement," said Andrew Blauvelt, MD, MBA[1], president of the Oregon Medical Research Center, in Portland, Oregon.

Upadacitinib also causes a different set of adverse reactions than dupilumab[2], he told Medscape Medical News.

Blauvelt presented the findings from the Heads Up[3] trial at the International Society of Atopic Dermatitis (ISAD) 2021 Annual Meeting.

The results of the phase 3 study suggest that upadacitinib, if approved for AD, will provide clinicians with another treatment option for patients who dont get adequate relief from either topical medications or dupilumab or who find these treatment...